Correlation analysis of FPGS rs10760502G>a polymorphism with prognosis and MTX-related toxicity in pediatric B-cell acute lymphoblastic leukemia.
10.7534/j.issn.1009-2137.2014.02.006
- Author:
Shu-Guang LIU
1
;
Chao GAO
2
;
Zhi-Gang LI
2
;
Wei-Jing LI
2
;
Lei CUI
2
;
Xiao-Xi ZHAO
2
;
Hu-Yong ZHENG
2
;
Min-Yuan WU
2
;
Rui-Dong ZHANG
2
;
Author Information
1. Hematology Oncology Center, Beijing Key Laboratory of Pediatric Hematology and Oncology; Key Laboratory of Major Diseases in Children, Ministry of Education; National Key Discipline of Pediatrics; Beijing Children's Hospital, Capital Medical University, Beijing 100045, China.
2. Hematology Oncology Center, Beijing Key Laboratory of Pediatric Hematology and Oncology
- Publication Type:Journal Article
- MeSH:
Adolescent;
Child;
Child, Preschool;
Female;
Genotype;
Humans;
Infant;
Leukemia, B-Cell;
diagnosis;
drug therapy;
genetics;
Male;
Methotrexate;
adverse effects;
Peptide Synthases;
genetics;
Polymorphism, Genetic;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
genetics;
Prognosis
- From:
Journal of Experimental Hematology
2014;22(2):291-297
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to explore the relation between folylpolyglutamate synthetase (FPGS) rs10760502 polymorphism and prognosis and methotrexate (MTX)-related toxicities in pediatric B-cell acute lymphoblastic leukemia (B-ALL). Sequenom MassARRAY was used to genotype rs10760502. The χ(2) test, Kaplan-Meier method and Cox regression models were used to analyze the data. The results indicated that A allele carriers (GA+AA) had poor relapse free survival (RFS, log-rank: P = 0.004) and event free survival (EFS, log-rank: P = 0.022) compared with the GG genotype carriers. Multivariate Cox-regression analysis results showed that A allele is an independent prognosis factor for poor RFS [hazard ratio (HR), 20.173; 95% CI, 2.535-160.545; P = 0.005] and EFS (HR, 8.133; 95% CI, 1.718-38.512; P = 0.008). No relationship was found between any MTX toxicity and rs10760502 polymorphism. It is concluded that FPGS rs10760502G>A polymorphism may affect the treatment outcome of B-ALL patients.
